OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...

In this conversation, Baligh Yehia, M.D., president of Jefferson Health, shares how the organization is rethinking healthcare ...

Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflowCERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ ...

Apogee Therapeutics (NASDAQ:APGE) is in focus as a scheduled quarterly reporting event today sharpens attention on clinical ...

The Canadian Center for Vaccinology researcher is recognized for advancing vaccine research that is shaping care for mothers, ...

Effective translation of the benefits of NRDL inclusion: 3 indications of 佳泰莱® and 达泰莱® have been included in the 2025 NRDL, which officially took effect on January 1, 2026. This marks 佳泰莱® the only ...

As autism prevalence reaches 1 in 31 children and diagnostic wait times for autism evaluations often extend four months or ...

Fate Therapeutics has initiated and treated the first patient in RECLAIM-LN, a Phase II clinical trial evaluating FT819 in patients with moderate-to-severe systemic lupus erythematosus (SLE) with ...

Ziresovir is said to be the first direct-acting RSV antiviral to complete a Phase III clinical trial with positive results.

Daraxonrasib, which is awaiting FDA approval, could double the life expectancy of people with advanced disease.

Rapid and accurate disease detection is essential for early intervention, risk stratification, treatment guidance, and prognosis evaluation. Recent advances ...

Indian IT services major Tata Consultancy Services (TCS) has launched an enterprise agentic AI platform aimed at helping ...